1 |
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
DOI
ScienceOn
|
2 |
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
DOI
ScienceOn
|
3 |
Nathan DM, Buse JB, Davidson MB, et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
DOI
ScienceOn
|
4 |
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
DOI
ScienceOn
|
5 |
Kahn SE, Haffner SM, Heise MA, et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
DOI
ScienceOn
|
6 |
Marchetti P, Lupi R, Del Guerra S, et al., Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 2009;32 Suppl 2:S178-83.
DOI
|
7 |
Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124:S3-18.
DOI
ScienceOn
|
8 |
Garber A, Henry R, Ratner R, et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, paralled-treatment trial. Lancet 2009;373:473-81.
DOI
ScienceOn
|
9 |
Marre M, Shaw J, Brandle M, et al., Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
DOI
ScienceOn
|
10 |
Nauck M, Frid A, Hermansen K, et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
DOI
ScienceOn
|
11 |
Zinman B, Gerich J, Buse JB, et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
DOI
ScienceOn
|
12 |
Buse JB, Rosenstock J, Sesti G, et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes; a 26- week randomized, parallel-groul, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
DOI
ScienceOn
|
13 |
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
DOI
ScienceOn
|
14 |
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87.
DOI
ScienceOn
|
15 |
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71.
DOI
ScienceOn
|
16 |
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther 2006;28:1556-68.
DOI
ScienceOn
|
17 |
Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009;29:55S-67S.
DOI
|
18 |
Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010;30:609-24.
DOI
ScienceOn
|
19 |
Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84.
DOI
ScienceOn
|
20 |
Rodbard HW, Jellinger PS, Davidson JA, et al., Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
DOI
ScienceOn
|
21 |
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
DOI
ScienceOn
|
22 |
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092- 100.
DOI
ScienceOn
|
23 |
Kendall DM, Riddle MC, Rosenstock J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
DOI
ScienceOn
|
24 |
Nauck MA, Duran S, Kim D, et al., A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin : a non-inferity study. Diabetologia 2007;50:259-67.
DOI
ScienceOn
|
25 |
Kim D, MacConell L, Zhuang D, et al., Effects of onceweekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93.
DOI
ScienceOn
|
26 |
Drucker DJ, Buse JB, Taylor K, et al., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50.
DOI
ScienceOn
|
27 |
FDA MedWatch: The FDA Safety Information and Adverse Event Reporting Program Website. Available at http://www.fda.gov/Safety/MedWatch/default.htm
|
28 |
Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368-73.
DOI
ScienceOn
|
29 |
DeFronzo RA, Hissa MN, Garber AJ, et al., The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-55.
DOI
ScienceOn
|
30 |
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drugnaive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-86.
DOI
ScienceOn
|
31 |
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8.
DOI
ScienceOn
|
32 |
Rosenstock J, Kim SW, Baron MA, et al., Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85.
DOI
ScienceOn
|
33 |
DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-7.
DOI
ScienceOn
|
34 |
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55.
DOI
ScienceOn
|
35 |
Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167-76.
DOI
ScienceOn
|
36 |
Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361-71.
DOI
ScienceOn
|